

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

MAR 2 0 1987

OFFICE OF
PESTICIDES AND TOXIC SUBSTANCES

MEMORANDUM

Tetramethrin - EPA Registration No. 10308-1 - Mouse SUBJECT:

Oncogenicity Study Issues Relating to Reformatted

Pathology Tables

Caswell No. 844 Record No. 187797 Project No. 7-0360

Accession Nos. 262776 to 262788

William Dykstra FROM:

Section II Reviewer

Toxicology Branch

William Dylotte 3/17/87 Hazard Evaluation Division (TS-769C)

TO: Paul Schroeder, PM Team 17

> Insecticide-Rodenticide Branch Registration Division (TS-767C)

THRU:

Edwin Budd, Section Head

Review Section II Toxicology Branch

Hazard Evaluation Division (TS-769C)

Action Requested

Respond to registrant's request for Toxicology Branch (TB) comments regarding reformatted pathology tables for the mouse oncogenicity study with tetramethrin.

Conclusions and Recommendations

Sample sheets of individual and summary histopathology incidence tables requested by TB are attached. The proposal to submit separate tables for neoplastic and non-neoplastic lesions are acceptable to TB, as is the format for reporting organ weights. Hazleton Laboratory's method of reporting individual histopathology findings is acceptable. However,

with respect to the laboratory's method of submitting histopathology incidence summary tables, TB requests that the sample sheet provided for summary incidence tables be followed.

The reason for TB position on the summary tables provided by Hazleton is that the Hazleton summary sheets do not specify animals that were scheduled sacrifices and moribund sacrifice/deaths but only provide the total numbers examined.

It should be noted that Hazleton Laboratory has recently (1986) submitted acceptable reformatted pathology tables corresponding to TB sample sheets for other chronic studies.

Attachments

SAMPLE SHEET

EVERY PATHOLOGY REPORT SHOULD HAVE INDIVIDUAL: STOPATHOLOGY INCIDENCE TABLE

Group 1

Male Mice Scheduled Sacrifices

A N 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	1 6 8 -4 7 4 X
LUNG X X X X X X X X X X X X X X X X X X X	113
LUNG X X X X X X X X X X X X X X X X X X X	
Alveolar/Bronchiolar Carcinoma Malignant Lymphoma Malignant Lymphoma, Undifferentiated	
Malignant Lymphoma Malignant Lymphoma, Undifferentiated	
Undifferentiated	18
	- 1g
Alveolar/Bronchiolar Adenoma	- 10
	3.45
Carcinoma, Metastatic	- 18
Granulocytic Leukemia	1000
Sarcoma, Metastatic P	18
	ી
Multifocal Pleuritis	100
Multifocal Pneumonitis 2	1
Alveolar Macrophages,	- 1
Pigmented 1	1
Focal Alveolar/Bronchiolar	
Hyperplasia	13
Congestion	4
Focal Hemorrhage	-13
Alveolar Macrophages	-18
Foci of Foamy Macrophages	- 13
Leukocytosis	- 10
Peribronchial/Vascular	
Mononuclear Cells 1 1 1 1 2 1 1	- 4
Alveolar Proteinosis	
Multifocal	1
Alveolar-Bronchiolitis 1	T
	1
	-

EVERY PATHOLOGY REPORT SHOULD HAVE: SUMMARY INCIDENCE TABLE

emaje Mice

emale Mice												
		Group 1			Group 5			Group 6			Group 7	
	Scheduled	Morlbund Sacrifice & Death	Fotei	Scheduled Sacrifice	Morlbund Sacrifice & Death	Fotel	Scheduled	Moribund Sacrifice & Death	Total	Scheduled Sacrifice	Moribund Sacrifice & Death	Totel
UNG (NO. EXAMINED)	(43)	(7)	(20)	(42)	(8)	(20)	(38)	(12)	(50)	(38)	(11)	(20)
Alveolar/Bronchiolar Carcinoma	2		2	2		2	2		2	3		
Malignant Lymphoma					1	1		4	4		1	1
Malignant Lymphoma, Undifferentiated		2	2				1		-		1	1
Alveolar/Bronchiolar Adenoma	က		3	3		3	5	2	7	4		4
Carcinoma, Metastatic	-	1	2		1	1		. 2	2			
Granulocytic Leukemia					1	1						
Sarcoma, Metastatic					•					v		
							-		•			ene y
Multifocal Pleuritis							1		1	3		3
Multifocal Pneumonitis	2		2	2		2	4		4	3		3
Alveolar Macrophages, Pigmented	7		7	4		4				1	-	•
Focal Alveolar/Bronchiolar												
llyperplasia	2		2	2		2	2		. 2	1		1
Congestion	2	2	4	4	5	9	3	5	8	3	8	11
Focal Hemorrhage				2		2	1		1	1		1
Alveolar Macrophages	2		2	2		2	2		. 2	1		-
Foct of Foamy Macrophages	4		4	3		3				2		2
Leukocytosis				1	2	3					3	3

STRATION DIVISION DATA REVIEW RECORD Confidential Business Information — Does Not Contain National Security Information (E.O. 12065) 1. CHEMICAL NAME 3. ACTION CODE 2. IDENTIFYING NUMBER TO BE COMPLETED BY PM 4. ACCESSION NUMBER 5. RECORD NUMBER 6. REFERENCE NUMBER i 7. DATE RECEIVED (EPA) 0 8. STATUTORY DUE DATE 9. PRODUCT MANAGER (PM) castille/Schroeder 10. PM TEAM NUMBER 14. CHECK IF APPLICABLE TO BE COMPLETED BY PCB 11. DATE SENT TO HED/TSS ☐ Public Health/Quarantine ☐ Minor Use 12. PRIORITY NUMBER Part of IPM ☐ Substitute Chemical 13. PROJECTED RETURN DATE Seasonal Concern Review Requires Less Than 4 Hours 15. INSTRUCTIONS TO REVIEWER A. HED C. BFSD Total Assessment - 3(c)(5) D. TSS/RD Incremental Risk Assessment -3(c)(7) and/or E.L. Johnson memo of May 12, 1977. E. D Other B. SPRD (Send Copy of Form to SPRD PM) Chemical Undergoing Active RPAR Review Chemical Undergoing Active Registration Standards Review 16. RELATED ACTIONS 18. REVIEWS SENT TO 17. 3(c)(1)(D) Use Any or All Available Information Use Only Attached Data Use Only the Attached Data for Formulation and Any or All Available Information on the Technical or Manufacturing Chemical. □ EF **В** тв DEEB PL Use Only Attached Data □ сн ☐ RCB ☐ EFB BFSD NUMBER OF ACTIONS TYPE OF REVIEW To Registration Petition EUP SLN Sec. 18 Inert MNR. USE Other TOXICOLOGY **ECOLOGICAL EFFECTS** ED RESIDUE CHEMISTRY **ENVIRONMENTAL DATE** CHEMISTRY **EFFICACY** PRECAUTIONARY LABELING **ECONOMIC ANALYSIS** 24. Include an Original and 4 (four) 23. Date Returned to RD Representative Label Submitted Confidential Labels Showing (to be completed by Copies of This Completed Form 20. With Application Statement of Accepted Uses HED) for Each Branch Checked for Attached Formula

Attached

Review.